Gildi lifeyrissjodur Makes New Investment in Oculis Holding AG $OCS

Key Points

• Gildi lifeyrissjodur acquired 2,447,985 shares of Oculis in Q4 (≈$50.25M), making the stock its second-largest holding at about 22.7% of the fund and representing roughly 4.67% of Oculis outstanding.
• Analyst sentiment is mixed but leans positive: seven analysts rate Oculis a Buy and one a Sell, producing a consensus rating of Moderate Buy with a consensus price target of $43.86; Needham and Stifel recently raised their targets.
• In its most recent quarter Oculis reported EPS of ($0.51) versus ($0.43) expected with $0.50M revenue, the stock trades near $27.48 (market cap ≈$1.59B), and the company shows strong liquidity ratios despite deeply negative margins and ROE.

Gildi lifeyrissjodur acquired a new stake in shares of Oculis Holding AG (NASDAQ:OCS - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 2,447,985 shares of the company's stock, valued at approximately $50,250,000. Oculis makes up approximately 22.7% of Gildi lifeyrissjodur's portfolio, making the stock its 2nd biggest holding. Gildi lifeyrissjodur owned about 4.67% of Oculis as of its most recent SEC filing.

Several other hedge funds have also recently modified their holdings of the stock. China Universal Asset Management Co. Ltd. increased its holdings in shares of Oculis by 100.0% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 2,000 shares of the company's stock valued at $40,000 after acquiring an additional 1,000 shares in the last quarter. Aberdeen Group plc increased its holdings in shares of Oculis by 39.4% during the fourth quarter. Aberdeen Group plc now owns 1,746,946 shares of the company's stock valued at $34,887,000 after acquiring an additional 493,827 shares in the last quarter. Compagnie Lombard Odier SCmA increased its holdings in shares of Oculis by 10.6% during the fourth quarter. Compagnie Lombard Odier SCmA now owns 107,300 shares of the company's stock valued at $2,143,000 after acquiring an additional 10,300 shares in the last quarter. Syquant Capital Sas acquired a new position in shares of Oculis during the fourth quarter valued at about $3,849,000. Finally, Aventura Private Wealth LLC acquired a new position in shares of Oculis during the fourth quarter valued at about $80,000. Institutional investors and hedge funds own 22.30% of the company's stock.

Analyst Upgrades and Downgrades

Several research firms have recently issued reports on OCS. Wall Street Zen downgraded shares of Oculis from a "hold" rating to a "sell" rating in a report on Saturday, March 7th. Needham & Company LLC upped their price objective on shares of Oculis from $36.00 to $40.00 and gave the company a "buy" rating in a report on Wednesday, March 4th. Stifel Nicolaus upped their price objective on shares of Oculis from $40.00 to $50.00 and gave the company a "buy" rating in a report on Wednesday, March 4th. Weiss Ratings restated a "sell (d-)" rating on shares of Oculis in a report on Tuesday, April 21st. Finally, HC Wainwright restated a "buy" rating and set a $44.00 price objective on shares of Oculis in a report on Monday, April 20th. Seven analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $43.86.

Oculis Price Performance

Shares of NASDAQ OCS opened at $27.48 on Friday. The business's 50 day moving average price is $27.04 and its 200 day moving average price is $23.98. The firm has a market cap of $1.59 billion, a P/E ratio of -12.11 and a beta of 0.38. Oculis Holding AG has a 52 week low of $16.00 and a 52 week high of $30.68. The company has a quick ratio of 5.96, a current ratio of 5.96 and a debt-to-equity ratio of 0.01.

Oculis (NASDAQ:OCS - Get Free Report) last issued its earnings results on Tuesday, March 3rd. The company reported ($0.51) EPS for the quarter, missing analysts' consensus estimates of ($0.43) by ($0.08). The firm had revenue of $0.50 million during the quarter, compared to analysts' expectations of $0.14 million. Oculis had a negative net margin of 8,173.41% and a negative return on equity of 62.12%. On average, sell-side analysts expect that Oculis Holding AG will post -2.17 earnings per share for the current year.

Oculis Company Profile

Oculis SA NASDAQ: OCS is a clinical-stage biopharmaceutical company focused on developing novel ophthalmic therapies designed primarily to treat retinal and neuro-ophthalmic diseases. Leveraging its proprietary technology platforms, Oculis aims to deliver therapeutic agents to the back of the eye through topical or nasal administration, potentially offering an alternative to current intravitreal injections. The company’s pipeline includes OCS-01, a topical dexamethasone formulation targeting diabetic macular edema; OCS-05, a neuroprotective candidate for acute optic neuritis and idiopathic intracranial hypertension; and OC-02, a nasal spray formulation of varenicline for dry eye disease.

Founded in 2016 and headquartered in Basel, Switzerland, Oculis operates research and development facilities across Europe and in the United States, with a presence in Cambridge, Massachusetts.

Want to see what other hedge funds are holding OCS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Oculis Holding AG (NASDAQ:OCS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.